Skip to content
Our reporters bring you news and highlights from BIO’s in-person and virtual events.
Established in 2012, the Pediatric Priority Review (PPRV) program offers a powerful incentive for companies to develop treatments for rare conditions affecting children. Even […]
BIO 2025: What is the PRV program and why does it matter? Read More »
Health equity should not be considered a parallel initiative, but a central pillar of the biotech industry’s strategy, said experts on Day 3 of
BIO 2025: Health equity as an engine for scalable innovation Read More »
The 2025 Biotechnology Innovation Organization (BIO) International Convention highlighted why we – the biotech industry – do what we do. In one word: patients.
BIO 2025: ‘Behind every data point there is a person’ Read More »
The rare disease patient community is the beating heart of the Biotechnology Innovation Organization’s (BIO) mission. Whether it is driving policy that supports innovation,
BIO 2025: Rare disease patients can’t wait Read More »
The threat to America’s leadership in biotech is a threat to our national security that we need to address now, two members of a
Biotech and national security: ‘Time to act but no time to wait’ Read More »
George W. Bush, 43rd President of the United States, headlined Tuesday’s mainstage with an exclusive conversation with Biotechnology Innovation Organization (BIO) President & CEO
BIO 2025: A few highlights from Day 2 Read More »
On Day 1 of the 2025 Biotechnology Innovation Organization (BIO) International Convention, a clear challenge was issued to the biotech industry: redefine how we understand,
BIO 2025: Let’s talk about sex (differences!) – specifically, women’s health Read More »
Pennsylvania is open for biotech business and working hard to grow the life sciences ecosystem that already exists in the state, according to Gov.
Pennsylvania’s Gov. Shapiro courts biotechs at BIO 2025 Read More »
Food and Drug Administration (FDA) Commissioner Martin A. Makary, M.D., M.P.H., sat down with the Biotechnology Innovation Organization (BIO) President and CEO John F.
BIO 2025: Commissioner Martin Makary, M.D., M.P.H., discusses vision for FDA Read More »
Public health advocates are reevaluating the vaccine landscape, revisiting long-held assumptions about vaccine policy during both public health emergencies and periods of relative calm.
BIO 2025: How do we talk about vaccines now? Read More »
